Changeflow GovPing Healthcare & Life Sciences Observational Survival Analysis, Epithelial Ova...
Routine Notice Added Final

Observational Survival Analysis, Epithelial Ovarian Carcinoma Patients

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

The National Institutes of Health registered an observational survival analysis study (NCT07540403) evaluating outcomes in epithelial ovarian carcinoma patients with unfavorable prognosis. The study aims to improve patient categorization and management by analyzing survival in recurrent disease patients. Conditions studied include ovarian cancer.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The NIH added a new clinical trial registry entry for an observational survival analysis study in patients with recurrent epithelial ovarian carcinoma and unfavorable prognosis. The study will evaluate patient characteristics, disease stage, and tumor genetic/molecular profiles to improve categorization and management.

Healthcare providers and clinical investigators involved in ovarian cancer research may reference this registry entry for awareness of ongoing survival analysis studies. The study registration has no direct compliance implications for external parties.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma

Observational NCT07540403 Kind: OBSERVATIONAL Apr 20, 2026

Abstract

Ovarian carcinoma is the most lethal gynecological malignancy. Epithelial ovarian carcinoma is the gynecological malignancy with the highest mortality rate. The prognosis of patients with recurrent disease is highly heterogeneous and is typically poor in cases of ovarian carcinoma with a progression-free survival (PFS) ≤ 6 months, for which therapeutic options are limited. However, it has been shown that patients with a PFS ≤ 6 months may not respond effectively to further treatments, whereas, conversely, patients with a PFS > 6 months could still benefit from them.

The classification of patients with recurrent disease has undergone continuous evolution over time. Essential factors to consider include patient characteristics, disease stage, and the precise genetic and molecular profile of the tumor. This study aims to evaluate survival in patients experiencing recurrence of epithelial ovarian carcinoma with an unfavorable prognosis, with the objective of improving patient categorization and management.

Conditions: Ovarian Cancer

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 20th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Healthcare providers Clinical investigators
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial registration Survival analysis study
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!